Blood platelets as an RNA biomarker platform for neuro-oncological diseases

Edward Post; Nik Sol; Myron G. Best; Thomas Wurdinger

doi:10.1093/noajnl/vdac043

Blood platelets as an RNA biomarker platform for neuro-oncological diseases

Edward Post
, Nik Sol
, Myron G. Best
, Thomas Wurdinger^*

^*Corresponding author for this work

Brain Tumor Center Amsterdam
Vrije Universiteit Amsterdam
Amsterdam UMC

Research output: Contribution to journal › Article › Academic › peer-review

25 Downloads (Pure)

Abstract

Blood-based liquid biopsies are an upcoming approach for earlier cancer detection, diagnostics, prognostics, therapy-response prediction, and therapy monitoring, including in patients with tumors of the central nervous system. Among these, liquid biopsies are plasma-derived markers such as cell-free DNA, RNA and proteins, extracellular vesicles, circulating glioma cells, immune cells, and blood platelets. Blood platelets are involved in the local and systemic response to the presence of cancer, thereby sequestering and splicing RNAs, which may be clinically useful as blood-based biomarkers. In this review, we discuss the available literature regarding the role of blood platelets in gliomas and provide suggestions for future research efforts.

Original language	English
Pages (from-to)	II61-II65
Journal	Neuro-oncology advances
Volume	4
Issue number	Suppl 2
DOIs	https://doi.org/10.1093/noajnl/vdac043 https://doi.org/10.1093/noajnl/vdac043
Publication status	Published - 1 Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

Blood-platelets-as-an-rna-biomarker-platform-for-neuro-oncological-diseases.pdfFinal published version, 975 KBLicence: CC BY

Cite this

@article{afec35acbe8f419292ac2963a8e52a8f,

title = "Blood platelets as an RNA biomarker platform for neuro-oncological diseases",

abstract = "Blood-based liquid biopsies are an upcoming approach for earlier cancer detection, diagnostics, prognostics, therapy-response prediction, and therapy monitoring, including in patients with tumors of the central nervous system. Among these, liquid biopsies are plasma-derived markers such as cell-free DNA, RNA and proteins, extracellular vesicles, circulating glioma cells, immune cells, and blood platelets. Blood platelets are involved in the local and systemic response to the presence of cancer, thereby sequestering and splicing RNAs, which may be clinically useful as blood-based biomarkers. In this review, we discuss the available literature regarding the role of blood platelets in gliomas and provide suggestions for future research efforts.",

author = "Edward Post and Nik Sol and Best, \{Myron G.\} and Thomas Wurdinger",

note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.",

year = "2022",

month = nov,

day = "1",

doi = "10.1093/noajnl/vdac043",

language = "English",

volume = "4",

pages = "II61--II65",

journal = "Neuro-oncology advances",

issn = "2632-2498",

publisher = "Oxford University Press",

number = "Suppl 2",

}

TY - JOUR

T1 - Blood platelets as an RNA biomarker platform for neuro-oncological diseases

AU - Post, Edward

AU - Sol, Nik

AU - Best, Myron G.

AU - Wurdinger, Thomas

N1 - © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

PY - 2022/11/1

Y1 - 2022/11/1

N2 - Blood-based liquid biopsies are an upcoming approach for earlier cancer detection, diagnostics, prognostics, therapy-response prediction, and therapy monitoring, including in patients with tumors of the central nervous system. Among these, liquid biopsies are plasma-derived markers such as cell-free DNA, RNA and proteins, extracellular vesicles, circulating glioma cells, immune cells, and blood platelets. Blood platelets are involved in the local and systemic response to the presence of cancer, thereby sequestering and splicing RNAs, which may be clinically useful as blood-based biomarkers. In this review, we discuss the available literature regarding the role of blood platelets in gliomas and provide suggestions for future research efforts.

AB - Blood-based liquid biopsies are an upcoming approach for earlier cancer detection, diagnostics, prognostics, therapy-response prediction, and therapy monitoring, including in patients with tumors of the central nervous system. Among these, liquid biopsies are plasma-derived markers such as cell-free DNA, RNA and proteins, extracellular vesicles, circulating glioma cells, immune cells, and blood platelets. Blood platelets are involved in the local and systemic response to the presence of cancer, thereby sequestering and splicing RNAs, which may be clinically useful as blood-based biomarkers. In this review, we discuss the available literature regarding the role of blood platelets in gliomas and provide suggestions for future research efforts.

UR - https://www.scopus.com/pages/publications/85159216259

UR - https://www.ncbi.nlm.nih.gov/pubmed/36380866

U2 - 10.1093/noajnl/vdac043

DO - 10.1093/noajnl/vdac043

M3 - Article

C2 - 36380866

SN - 2632-2498

VL - 4

SP - II61-II65

JO - Neuro-oncology advances

JF - Neuro-oncology advances

IS - Suppl 2

ER -

Blood platelets as an RNA biomarker platform for neuro-oncological diseases

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this